NEW YORK – Swedish biotech company Oblique Therapeutics on Wednesday announced that it has raised 98M SEK ($11.4M) in an investment round led by Västra Hamnen Corporate Finance, and plans to use the funds in part to discover selective antibody therapeutics to treat KRAS-mutated cancers.
To read the full story....
...and receive Weekly News bulletins.
Already have a Precision Oncology News or 360Dx or GenomeWeb account?
Login Now.
Don't have a Precision Oncology News or 360Dx or GenomeWeb account?
Register for Free.